Interviews

Courtney D. DiNardo, MD, discusses the current treatment landscape for patients with IDH1-mutated acute myeloid leukemia and how potential doublet and triplet combinations may play a role in this setting.

Michael Wang, MD, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial.

John Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.

Marcia Brose, MD, PhD, discusses the treatment options for patients with thyroid cancer and NTRK fusions.

Mansoor R. Mirza, MD, discusses the results of the PRIMA study of niraparib in patients with advanced ovarian cancer and the evaluation of the starting dose in these patients.

Scott Tykodi, MD, PhD, discusses recent findings in the KEYNOTE-427 trial of pembrolizumab in patients with renal cell carcinoma.

Richard S. Finn, MD, discusses how he sees the field of hepatocellular carcinoma evolving in the future.

A. Oliver Sartor, MD, discusses the design for an observational study of disease characteristics and outcome of patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA after receiving radium-223.

Jesus Berdeja, MD, discusses the next steps for the chimeric antigen receptor T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 trial in patients with relapsed/refractory multiple myeloma.

Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

Christina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Scott Kopetz, MD, PhD, discusses the next steps following the phase 3 BEACON CRC trial of encorafenib plus cetuximab with or without binimetinib compared with irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E metastatic colorectal cancer.

Jennifer Marie Suga, MD, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing testing of patients with advanced cancers in the community setting.

Yeon Hee Park, MD, discusses the data supporting the FDA’s accelerated approval of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.

Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.

Brian M. Slomovitz, MD, discusses the some of the subcategories of endometrial cancer and how the make a difference for patients’ treatment.

Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.

Winston Tan, MD, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor lenvatinib and another TKI, sorafenib.

A group of physicians in gynecologic oncology spoke to the challenges they have seen in their clinics in the face of the COVID-19 pandemic.

Charles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.

Bradley J. Monk, MD, FACS, FACOG, discusses the remaining challenges in conducting clinical trials for patients with cervical cancer.

Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.

Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.

Enrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.

Georgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.

Jerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.

Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.

David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.

Van K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.

Jae Park, MD, discusses adverse events associated with chimeric antigen receptor T-cell therapies, such as neurotoxicity, for patients with acute lymphocytic leukemia.